Synthesis of 2-methoxybenzamide derivatives and evaluation of their hedgehog signaling pathway inhibition.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
27
01
2021
accepted:
22
06
2021
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
29
4
2022
Statut:
epublish
Résumé
Aberrant hedgehog (Hh) signaling is implicated in the development of a variety of cancers. Smoothened (Smo) protein is a bottleneck in the Hh signal transduction. The regulation of the Hh signaling pathway to target the Smo receptor is a practical approach for development of anticancer agents. We report herein the design and synthesis of a series of 2-methoxybenzamide derivatives as Hh signaling pathway inhibitors. The pharmacological data demonstrated that compound 21 possessed potent Hh pathway inhibition with a nanomolar IC
Identifiants
pubmed: 35480433
doi: 10.1039/d1ra00732g
pii: d1ra00732g
pmc: PMC9034380
doi:
Types de publication
Journal Article
Langues
eng
Pagination
22820-22825Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Nature. 2013 May 16;497(7449):338-43
pubmed: 23636324
Crit Rev Oncol Hematol. 2016 Feb;98:235-41
pubmed: 26614022
Sci Rep. 2017 May 10;7(1):1665
pubmed: 28490735
Eur J Med Chem. 2017 Jan 5;125:1036-1050
pubmed: 27810591
Leukemia. 2019 Feb;33(2):379-389
pubmed: 30555165
Chem Biol. 2011 Apr 22;18(4):432-7
pubmed: 21513879
Sci Signal. 2015 Jun 02;8(379):ra55
pubmed: 26038600
J Med Chem. 2019 Sep 26;62(18):8392-8411
pubmed: 30986059
Bioorg Med Chem Lett. 2018 Oct 15;28(19):3131-3140
pubmed: 30177379
Science. 2009 Oct 23;326(5952):572-4
pubmed: 19726788
Cancer Cell. 2015 Mar 9;27(3):342-53
pubmed: 25759020
Expert Opin Ther Pat. 2009 Aug;19(8):1039-56
pubmed: 19505195
Org Biomol Chem. 2017 Apr 5;15(14):3046-3059
pubmed: 28318003
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9736-41
pubmed: 20460306
Nature. 2016 Jul 28;535(7613):517-522
pubmed: 27437577
J Neurooncol. 2011 Dec;105(3):475-83
pubmed: 21633906
Nature. 2020 Apr;580(7803):396-401
pubmed: 32296180
Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10369-E10378
pubmed: 29133390
Cancer Treat Rev. 2019 Jun;76:41-50
pubmed: 31125907
Bioorg Med Chem. 2009 Jul 15;17(14):4943-54
pubmed: 19541490
Bioorg Med Chem. 2020 Mar 15;28(6):115354
pubmed: 32063403
Nat Chem Biol. 2015 Apr;11(4):246-55
pubmed: 25785427
J Med Chem. 2011 Apr 28;54(8):2592-601
pubmed: 21438527
Nature. 2018 Oct;562(7727):429-433
pubmed: 30297801
Med Res Rev. 2018 May;38(3):870-913
pubmed: 29315702
Lancet. 2020 Mar 28;395(10229):1078-1088
pubmed: 32222192
Nature. 2009 Apr 9;458(7239):776-9
pubmed: 19169242
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Cell Rep. 2017 Jun 6;19(10):2074-2087
pubmed: 28591579
Mol Pharm. 2015 Apr 6;12(4):1289-98
pubmed: 25679326
ACS Med Chem Lett. 2011 Dec 21;3(2):106-11
pubmed: 24900436
Drug Discov Today. 2018 Mar;23(3):704-710
pubmed: 29326074
Eur J Med Chem. 2018 Sep 5;157:368-379
pubmed: 30099257
J Am Chem Soc. 2017 Sep 13;139(36):12559-12568
pubmed: 28759213
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6
pubmed: 12391318
Biochem Pharmacol. 2013 Mar 1;85(5):623-628
pubmed: 23148911
Nature. 2019 Jul;571(7764):284-288
pubmed: 31263273
Onco Targets Ther. 2017 Mar 16;10:1645-1653
pubmed: 28352196
Pharmacol Res. 2019 Mar;141:466-480
pubmed: 30639373
ACS Chem Biol. 2012 Jun 15;7(6):1040-8
pubmed: 22554036